Brief: Neoimmunetech Announces First Patient Dosed In The Pilot Study Of NT-I7 In Progressive Multifocal Leukoencephalopathy
24/05/2021 12:11
May 24 (Reuters) - Neoimmunetech Inc (Pre-reincorporation)
950220.KQ :
* NEOIMMUNETECH ANNOUNCES FIRST PATIENT DOSED IN THE PILOT
STUDY
OF NT-I7 (EFINEPTAKIN ALFA) IN PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATHY
Source text for Eikon: ID:nBw4yhTZca
Further company coverage: 950220.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neoimmunetech
See all newsBrief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment
Brief: Neoimmunetech Presents Phase 1 Study Data At Society For Neuro-Oncology Annual Meeting